Terminal and progenitor lineage-survival oncogenes as cancer markers

Trends in Molecular Medicine

Volumn 14, Issue 11, 2008, Pages 486-494

  Vias, Maria ^a   Ramos Montoya, Antonio ^a   Mills, Ian G ^a  

^a CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS E26 HOMOLOGUE TRANSCRIPTION FACTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ESTROGEN RECEPTOR; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR HOXA7; TRANSCRIPTION FACTOR HOXB7; TRANSCRIPTION FACTOR HOXC6; TRANSCRIPTION FACTOR HOXC8; TRANSCRIPTION FACTOR HOXD9; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL ISOLATION; CELL LINEAGE; CELL NUCLEUS; CELL STRUCTURE; CELL SUBPOPULATION; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; NERVOUS SYSTEM DEVELOPMENT; NEUROENDOCRINE TUMOR; ONCOGENE; STEM CELL; TUMOR CLASSIFICATION; TUMOR GROWTH;

ANIMALS; CELL LINEAGE; CHROMATIN IMMUNOPRECIPITATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; SIGNAL TRANSDUCTION; STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 54249138178     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2008.09.002     Document Type: Article

References (84)

1. Weinstein I.B. Cancer. addiction to oncogenes - the Achilles heal of cancer. Science 297 (2002) 63-64
2. Garraway L.A., and Sellers W.R. Lineage dependency and lineage-survival oncogenes in human cancer. Nat. Rev. Cancer 6 (2006) 593-602
3. Garraway L.A., and Sellers W.R. From integrated genomics to tumor lineage dependency. Cancer Res. 66 (2006) 2506-2508
4. Garraway L.A., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436 (2005) 117-122
5. Kono M., et al. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol. Cancer Res. 4 (2006) 779-792
6. Houben R., et al. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J. Invest. Dermatol. 128 (2008) 2003-2012
7. Waltregny D., et al. Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol. Endocrinol. 15 (2001) 765-782
8. Berger R., et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 64 (2004) 8867-8875
9. Schneider H.P., and Bocker W. Hormones and progeny of breast tumor cells. Climacteric 9 (2006) 88-107
10. Gutierrez-Hartmann A., et al. ETS transcription factors in endocrine systems. Trends Endocrinol. Metab. 18 (2007) 150-158
11. Turner D.P., et al. Defining ETS transcription regulatory networks and their contribution to breast cancer progression. J. Cell. Biochem. 102 (2007) 549-559
12. Seth A., and Watson D.K. ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer 41 (2005) 2462-2478
13. Kurpios N.A., et al. Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis. J. Mammary Gland Biol. Neoplasia 8 (2003) 177-190
14. Wigle J.T., and Eisenstat D.D. Homeobox genes in vertebrate forebrain development and disease. Clin. Genet. 73 (2008) 212-226
15. Takahashi Y., et al. Expression profiles of 39 HOX genes in normal human adult organs and anaplastic thyroid cancer cell lines by quantitative real-time RT-PCR system. Exp. Cell Res. 293 (2004) 144-153
16. Calvo R., et al. Altered HOX and WNT7A expression in human lung cancer. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12776-12781
17. Li H., et al. Expression of homeobox genes in cervical cancer. Gynecol. Oncol. 84 (2002) 216-221
18. Miller G.J., et al. Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res. 63 (2003) 5879-5888
19. Waltregny D., et al. Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation. Prostate 50 (2002) 162-169
20. Quentmeier H., et al. Expression of HOX genes in acute leukemia cell lines with and without MLL translocations. Leuk. Lymphoma 45 (2004) 567-574
21. Moore M.A., et al. NUP98 dysregulation in myeloid leukemogenesis. Ann. N. Y. Acad. Sci. 1106 (2007) 114-142
22. McCabe C.D., et al. Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer. Cancer Res. 68 (2008) 1988-1996
23. Vias M., et al. Pro-neural transcription factors as cancer markers. BMC Med. Genomics 1 (2008) 17
24. Taniwaki M., et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int. J. Oncol. 29 (2006) 567-575
25. Chen H., et al. Medullary thyroid cancer: the functions of raf-1 and human achaete-scute homologue-1. Thyroid 15 (2005) 511-521
26. Shida T., et al. Aberrant expression of human achaete-scute homologue gene 1 in the gastrointestinal neuroendocrine carcinomas. Clin. Cancer Res. 11 (2005) 450-458
27. Ball D.W. Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer. Cancer Lett. 204 (2004) 159-169
28. Visakorpi T., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9 (1995) 401-406
29. Kageyama R., et al. Roles of bHLH genes in neural stem cell differentiation. Exp. Cell Res. 306 (2005) 343-348
30. Chapouton P., et al. The transcription factor neurogenin 2 restricts cell migration from the cortex to the striatum. Development 128 (2001) 5149-5159
31. Cornell R.A., and Eisen J.S. Notch in the pathway: the roles of Notch signaling in neural crest development. Semin. Cell Dev. Biol. 16 (2005) 663-672
32. Quan X.J., and Hassan B.A. From skin to nerve: flies, vertebrates and the first helix. Cell. Mol. Life Sci. 62 (2005) 2036-2049
33. Gohlke J.M., et al. Characterization of the proneural gene regulatory network during mouse telencephalon development. BMC Biol. 6 (2008) 15
34. Bertrand N., et al. Proneural genes and the specification of neural cell types. Nat. Rev. Neurosci. 3 (2002) 517-530
35. Garcia-Yuste M., et al. Neuroendocrine tumors of the lung. Curr. Opin. Oncol. 20 (2008) 148-154
36. Hoff A.O., and Hoff P.M. Medullary thyroid carcinoma. Hematol. Oncol. Clin. North Am. 21 (2007) 475-488
37. Cindolo L., et al. Neuroendocrine differentiation in prostate cancer: from lab to bedside. Urol. Int. 79 (2007) 287-296
38. Lubensky I.A., and Zhuang Z. Molecular genetic events in gastrointestinal and pancreatic neuroendocrine tumors. Endocr. Pathol. 18 (2007) 156-162
39. Carnaghi C., et al. Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer. Ann. Oncol. 12 Suppl. 2 (2001) S119-S123
40. Wafa L.A., et al. Isolation and identification of l-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system. Biochem. J. 375 (2003) 373-383
41. Uccella S., et al. Histidine decarboxylase, DOPA decarboxylase, and vesicular monoamine transporter 2 expression in neuroendocrine tumors: immunohistochemical study and gene expression analysis. J. Histochem. Cytochem. 54 (2006) 863-875
42. Ranno S., et al. The chromogranin-A (CgA) in prostate cancer. Arch. Gerontol. Geriatr. 43 (2006) 117-126
43. Slodkowska J., et al. Neuroendocrine phenotype of non-small cell lung carcinoma: immunohistological evaluation and biochemical study. Int. J. Biol. Markers 20 (2005) 217-226
44. Nisman B., et al. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer. Tumour Biol. 27 (2006) 8-16
45. Blagosklonny M.V. Apoptosis, proliferation, differentiation: in search of the order. Semin. Cancer Biol. 13 (2003) 97-105
46. Nakano I., et al. Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J. Cell Biol. 170 (2005) 413-427
47. Gurok U., et al. Laser capture microdissection and microarray analysis of dividing neural progenitor cells from the adult rat hippocampus. Eur. J. Neurosci. 26 (2007) 1079-1090
48. Shin S., et al. Whole genome analysis of human neural stem cells derived from embryonic stem cells and stem and progenitor cells isolated from fetal tissue. Stem Cells 25 (2007) 1298-1306
49. Dougherty J.D., et al. PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase. J. Neurosci. 25 (2005) 10773-10785
50. Ozen I., et al. Proliferating neuronal progenitors in the postnatal hippocampus transiently express the proneural gene Ngn2. Eur. J. Neurosci. 25 (2007) 2591-2603
51. Vaccaro A., et al. In vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anticancer Drugs 17 (2006) 849-853
52. Kunnimalaiyaan M., et al. Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery 138 (2005) 1137-1142
53. Kunnimalaiyaan M., et al. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J. Biol. Chem. 281 (2006) 39819-39830
54. Sriuranpong V., et al. Notch signaling induces rapid degradation of achaete-scute homolog 1. Mol. Cell. Biol. 22 (2002) 3129-3139
55. Sriuranpong V., et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 61 (2001) 3200-3205
56. Greenblatt D.Y., et al. Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Ann. Surg. 247 (2008) 1036-1040
57. Osada H., et al. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res. 65 (2005) 10680-10685
58. Nakai N., et al. Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. Gene Ther. 14 (2007) 357-365
59. Signoretti S., and Loda M. Prostate stem cells: from development to cancer. Semin. Cancer Biol. 17 (2007) 219-224
60. Gupta P.K. Single-molecule DNA sequencing technologies for future genomics research. Trends Biotechnol. 26 (2008) 602-611
61. Mardis E.R. Next-generation DNA sequencing methods. Annu. Rev. Genomics Hum. Genet. 9 (2008) 387-402
62. Acevedo L.G., et al. Genome-scale ChIP-chip analysis using 10,000 human cells. Biotechniques 43 (2007) 791-797
63. Komashko V.M., et al. Using ChIP-chip technology to reveal common principles of transcriptional repression in normal and cancer cells. Genome Res. 18 (2008) 521-532
64. Massie C.E., and Mills I.G. ChIPping away at gene regulation. EMBO Rep. 9 (2008) 337-343
65. Shand R.L., and Gelmann E.P. Molecular biology of prostate-cancer pathogenesis. Curr. Opin. Urol. 16 (2006) 123-131
66. Massie C.E., et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep. 8 (2007) 871-878
67. Gown A.M. Current issues in ER and HER2 testing by IHC in breast cancer. Mod. Pathol. 21 Suppl 2 (2008) S8-S15
68. Carroll J.S., et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122 (2005) 33-43
69. Ozsolak F., et al. High-throughput mapping of the chromatin structure of human promoters. Nat. Biotechnol. 25 (2007) 244-248
70. Turner D.P., and Watson D.K. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev. Anticancer Ther. 8 (2008) 33-42
71. Khoury J.D. Ewing sarcoma family of tumors: a model for the new era of integrated laboratory diagnostics. Expert Rev. Mol. Diagn. 8 (2008) 97-105
72. Hollenhorst P.C., et al. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev. 21 (2007) 1882-1894
73. Kwei K.A., et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 27 (2008) 3635-3640
74. Lappin T.R., et al. HOX genes: seductive science, mysterious mechanisms. Ulster Med. J. 75 (2006) 23-31
75. Kwei K.A., et al. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet. 4 (2008) e1000081
76. Schmitz G. Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide. Curr. Opin. Mol. Ther. 8 (2006) 547-554
77. Wong S., and Witte O.N. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol. 22 (2004) 247-306
78. Brukner I. INGN-201. Introgen Therapeutics. Curr. Opin. Investig. Drugs 2 (2001) 1776-1785
79. Xodo L.E., et al. Anti-gene strategies to down-regulate gene expression in mammalian cells. Curr. Pharm. Des. 10 (2004) 805-819
80. Shirakawa T., et al. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum. Gene Ther. 18 (2007) 1225-1232
81. Leong K.G., and Gao W.Q. The Notch pathway in prostate development and cancer. Differentiation 76 (2008) 699-716
82. Ito T., et al. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development 127 (2000) 3913-3921
83. Fiuza U.M., and Arias A.M. Cell and molecular biology of Notch. J. Endocrinol. 194 (2007) 459-474
84. Taniguchi Y. LIM protein KyoT2 negatively regulates transcription by association with the RBP-J DNA-binding protein. Mol. Cell. Biol. 18 (1988) 644-654